[Evolution of reimbursement of high-cost anticancer drugs: Financial impact within a university hospital].

Introduction: In the context of health expenses control, reimbursement of high-cost medicines with a 'minor' or 'nonexistent' improvement in actual health benefit evaluated by the Haute Autorité de santé is revised by the decree of March 24, 2016 related to the procedure and terms of registration of high-cost pharmaceutical drugs. This study aims to set up the economic impact of this measure.

Method: A six months retrospective study was conducted within a French university hospital from July 1, 2015 to December 31, 2015.